The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial



McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit
et al (show 1 more authors) (2021) The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 23 (4). 1020 - 1029.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Uncontrolled Keywords: cost-effectiveness, dapagliflozin, SGLT2 inhibitor, type 2 diabetes
Depositing User: Symplectic Admin
Date Deposited: 11 Feb 2021 10:37
Last Modified: 07 Dec 2021 08:10
DOI: 10.1111/dom.14308
Open Access URL: https://doi.org/10.1111/dom.14308
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3115487